nadolol has been researched along with salmeterol xinafoate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Charlton, SJ; Dickson, CJ; Duca, JS; Fairhurst, RA; Hornak, V; McKay, DJ; Pearlstein, RA; Reilly, J; Sandham, DA; Shaw, D; Sykes, DA; Velez-Vega, C | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
2 other study(ies) available for nadolol and salmeterol xinafoate
| Article | Year |
|---|---|
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
Topics: Binding Sites; Cell Membrane; Dose-Response Relationship, Drug; Humans; Ligands; Models, Molecular; Molecular Structure; Receptors, Adrenergic, beta-2; Structure-Activity Relationship | 2016 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |